AU2292092A - Tumor, carbohydrate antigen specific monoclonal antibody and cell line - Google Patents

Tumor, carbohydrate antigen specific monoclonal antibody and cell line

Info

Publication number
AU2292092A
AU2292092A AU22920/92A AU2292092A AU2292092A AU 2292092 A AU2292092 A AU 2292092A AU 22920/92 A AU22920/92 A AU 22920/92A AU 2292092 A AU2292092 A AU 2292092A AU 2292092 A AU2292092 A AU 2292092A
Authority
AU
Australia
Prior art keywords
cell line
monoclonal antibody
tumor
antigen specific
specific monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22920/92A
Other languages
English (en)
Inventor
Jan Holmgren
Peter Lind
Leif Lindholm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Publication of AU2292092A publication Critical patent/AU2292092A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU22920/92A 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line Abandoned AU2292092A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody
SE9102074 1991-07-03

Publications (1)

Publication Number Publication Date
AU2292092A true AU2292092A (en) 1993-02-11

Family

ID=20383243

Family Applications (2)

Application Number Title Priority Date Filing Date
AU22920/92A Abandoned AU2292092A (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line
AU19425/92A Ceased AU658198B2 (en) 1991-07-03 1992-07-03 Tumour antigen specific antibody, its use and cell in line producing the antibody

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU19425/92A Ceased AU658198B2 (en) 1991-07-03 1992-07-03 Tumour antigen specific antibody, its use and cell in line producing the antibody

Country Status (19)

Country Link
US (1) US5552293A (https=)
EP (1) EP0521842B1 (https=)
JP (1) JP3194020B2 (https=)
KR (1) KR100246681B1 (https=)
AT (1) ATE171193T1 (https=)
AU (2) AU2292092A (https=)
CA (1) CA2073124C (https=)
DE (1) DE69226990T2 (https=)
DK (1) DK0521842T3 (https=)
EE (1) EE03031B1 (https=)
ES (1) ES2124250T3 (https=)
FI (1) FI109207B (https=)
HU (2) HU218084B (https=)
IE (1) IE80841B1 (https=)
IL (1) IL102390A (https=)
NO (1) NO315472B1 (https=)
NZ (1) NZ243435A (https=)
SE (1) SE9102074D0 (https=)
WO (2) WO1993001302A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004537976A (ja) 2001-03-15 2004-12-24 インターナショナル バイオイムン システムズ，インコーポレーテッド 膵癌のモノクローナル抗体治療
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
JP2005532395A (ja) * 2002-07-02 2005-10-27 スミスクライン・ビーチャム・コーポレイション 新規な安定処方
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA05011811A (es) 2003-05-20 2006-02-17 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinoides.
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
KR101527334B1 (ko) * 2005-08-11 2015-06-09 알피 마토씨안-로저스 자가면역 질병의 치료 및 진단용 ｔｃｒ-ｖ-베타 관련 펩티드
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
MX2011001445A (es) 2008-08-05 2011-04-05 Toray Industries Metodo para detectar cancer.
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
KR20250071286A (ko) 2016-01-10 2025-05-21 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
CA3139899A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
EP4732850A1 (en) 2024-10-25 2026-04-29 Antelope Therapeutics SAS Antibody-drug conjugates and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
AU657483B2 (en) * 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
DE69122777T2 (de) * 1990-07-20 1997-04-10 Pharmacia & Upjohn Ab, Stockholm Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation

Also Published As

Publication number Publication date
CA2073124C (en) 2007-06-19
FI109207B (fi) 2002-06-14
IL102390A0 (en) 1993-01-14
JPH05276987A (ja) 1993-10-26
IE922188A1 (en) 1993-01-13
NZ243435A (en) 1994-10-26
HU211512A9 (en) 1995-11-28
AU1942592A (en) 1993-01-07
JP3194020B2 (ja) 2001-07-30
KR100246681B1 (ko) 2000-04-01
WO1993001302A1 (en) 1993-01-21
WO1993001303A1 (en) 1993-01-21
EP0521842A3 (https=) 1994-01-26
DE69226990T2 (de) 1999-03-25
IE80841B1 (en) 1999-03-24
FI935970A0 (fi) 1993-12-31
IL102390A (en) 1996-01-19
NO934777D0 (no) 1993-12-22
AU658198B2 (en) 1995-04-06
CA2073124A1 (en) 1993-01-04
EP0521842B1 (en) 1998-09-16
DE69226990D1 (de) 1998-10-22
EE03031B1 (et) 1997-08-15
HUT71193A (en) 1995-11-28
EP0521842A2 (en) 1993-01-07
SE9102074D0 (sv) 1991-07-03
HU9400011D0 (en) 1994-05-30
US5552293A (en) 1996-09-03
ES2124250T3 (es) 1999-02-01
DK0521842T3 (da) 1999-06-14
FI935970L (fi) 1993-12-31
HU218084B (hu) 2000-05-28
NO315472B1 (no) 2003-09-08
ATE171193T1 (de) 1998-10-15
NO934777L (no) 1994-02-11

Similar Documents

Publication Publication Date Title
AU2292092A (en) Tumor, carbohydrate antigen specific monoclonal antibody and cell line
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
AU2097692A (en) Method for the production of monoclonal antibodies utilizing a germfree animal
EP0597829A4 (en) MONOCLONAL ANTIBODIES AGAINST A NEW ANTIQUE ASSOCIATED WITH HUMAN TUMORS.
AU7121191A (en) Diagnostic assay for alzheimer's disease
DE3684211D1 (https=)
CA2192079A1 (en) Human Monoclonal Antibodies Specific to Cell Cycle Independent Glioma Surface Antigen
EP0218158A3 (en) Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody.
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
AU2484488A (en) Method for the production of antigenic protein-hapten conjugates, and antibodies corresponding thereto
AU4465489A (en) Monoclonal antibody specifically recognizing n-glycolyl type gm2 hybridoma producing the antibody and method for preparing the hybridoma
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
AU2687992A (en) Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof
CA2008735A1 (en) Human epidermal growth factor (egf) receptor sequences and egf competitive monoclonal antibodies
ES2053507T3 (es) Un metodo para producir anticuerpos lym-2.
GR3024188T3 (en) Method of preparing 17-oxosteroids
AU8819391A (en) Antibody reactive to hamster immunoglobulins
IT8020164A0 (it) Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina.